drugset / Trial / NCT05104216
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD
Phase 4
Unknown
400 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabZhejiang Provincial Center for Disease Control and Prevention · collab
NaSingle-groupOpen-labelPrevention
Summary
Evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated COVID-19 vaccine .
Timeline
- Start
- 2021-12
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoronaVac | Vaccine | — | — |